Viridian Therapeutics
VRDN
169 hedge funds and large institutions have $2.01B invested in Viridian Therapeutics in 2025 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 53 increasing their positions, 65 reducing their positions, and 18 closing their positions.
52% more capital invested
Capital invested by funds: $1.32B → $2.01B (+$689M)
20% more funds holding in top 10
Funds holding in top 10: 10 → 12 (+2)
1% less funds holding
Funds holding: 170 → 169 (-1)
6% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 18
1.76% less ownership
Funds ownership: 115.89% → 114.13% (-1.8%)
18% less repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 65
52% less call options, than puts
Call options by funds: $1.02M | Put options by funds: $2.14M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
+$18.3M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$15.4M |
| 3 |
Fisher Asset Management
Camas,
Washington
|
+$12.5M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$9.93M |
| 5 |
RHJA
Rice Hall James & Associates
San Diego,
California
|
+$6.06M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Commodore Capital
New York
|
-$30.2M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$10.3M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$8.61M |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$6.11M |
| 5 |
IC
Ikarian Capital
Dallas,
Texas
|
-$4.05M |
VRDN Hedge Fund Activity: Q3 2025 in Review
169 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Viridian Therapeutics (VRDN) for Q3 2025, worth a combined $2.01B — up 52% from $1.32B a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of VRDN and 17 opened new positions — a net loss of 1 holder — while 65 trimmed existing stakes and 53 added.
The largest buyer was Perceptive Advisors, adding an estimated $18.3M. The largest seller was Commodore Capital, cutting an estimated $30.2M.
- 169 institutional investors held Viridian Therapeutics (VRDN) as of Q3 2025, down from 170 in Q2 2025.
- Funds reported $2.01B of Viridian Therapeutics stock for Q3 2025, up 52% quarter-over-quarter.
- 17 funds opened new Viridian Therapeutics positions in Q3 2025 and 18 closed out, a net change of -1 holder.
- The largest Viridian Therapeutics buyer in Q3 2025 was Perceptive Advisors, an estimated $18.3M added.
- The largest Viridian Therapeutics seller in Q3 2025 was Commodore Capital, an estimated $30.2M sold.
Based on aggregated 13F filings for Q3 2025.